🚀 VC round data is live in beta, check it out!
Personalis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Personalis and similar public comparables like Castle Biosciences, Takara Bio, Abclon, Mirxes Holding and more.
Personalis Overview
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Founded
2011
HQ
Employees
229
Website
Financials (LTM)
EV
$694M
Personalis Financials
Personalis reported last 12-month revenue of $72M and negative EBITDA of ($83M).
In the same LTM period, Personalis generated $15M in gross profit, ($83M) in EBITDA losses, and had net loss of ($86M).
Revenue (LTM)
Personalis P&L
In the most recent fiscal year, Personalis reported revenue of $70M and EBITDA of ($71M).
Personalis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $72M | XXX | $70M | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | $16M | XXX | XXX | XXX |
| Gross Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBITDA | ($83M) | XXX | ($71M) | XXX | XXX | XXX |
| EBITDA Margin | (116%) | XXX | (102%) | XXX | XXX | XXX |
| EBIT Margin | (130%) | XXX | (126%) | XXX | XXX | XXX |
| Net Profit | ($86M) | XXX | ($81M) | XXX | XXX | XXX |
| Net Margin | (121%) | XXX | (117%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Personalis Stock Performance
Personalis has current market cap of $804M, and enterprise value of $694M.
Market Cap Evolution
Personalis' stock price is $9.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $694M | $804M | 0.0% | XXX | XXX | XXX | $-0.92 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPersonalis Valuation Multiples
Personalis trades at 9.7x EV/Revenue multiple, and (8.4x) EV/EBITDA.
EV / Revenue (LTM)
Personalis Financial Valuation Multiples
As of March 21, 2026, Personalis has market cap of $804M and EV of $694M.
Equity research analysts estimate Personalis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Personalis has a P/E ratio of (9.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $804M | XXX | $804M | XXX | XXX | XXX |
| EV (current) | $694M | XXX | $694M | XXX | XXX | XXX |
| EV/Revenue | 9.7x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBITDA | (8.4x) | XXX | (9.8x) | XXX | XXX | XXX |
| EV/EBIT | (7.5x) | XXX | (7.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 45.6x | XXX | 44.0x | XXX | XXX | XXX |
| P/E | (9.3x) | XXX | (9.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Personalis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Personalis Margins & Growth Rates
Personalis' revenue in the last 12 month grew by 19%.
Personalis' revenue per employee in the last FY averaged $0.3M.
Personalis' rule of 40 is (97%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Personalis' rule of X is (68%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Personalis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | (116%) | XXX | (102%) | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 42% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (97%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (68%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 72% | XXX | 72% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 149% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Personalis Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Castle Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Takara Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Abclon | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirxes Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Personalis M&A Activity
Personalis acquired XXX companies to date.
Last acquisition by Personalis was on XXXXXXXX, XXXXX. Personalis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Personalis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPersonalis Investment Activity
Personalis invested in XXX companies to date.
Personalis made its latest investment on XXXXXXXX, XXXXX. Personalis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Personalis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Personalis
| When was Personalis founded? | Personalis was founded in 2011. |
| Where is Personalis headquartered? | Personalis is headquartered in United States. |
| How many employees does Personalis have? | As of today, Personalis has over 229 employees. |
| Who is the CEO of Personalis? | Personalis' CEO is Christopher Hall. |
| Is Personalis publicly listed? | Yes, Personalis is a public company listed on Nasdaq. |
| What is the stock symbol of Personalis? | Personalis trades under PSNL ticker. |
| When did Personalis go public? | Personalis went public in 2019. |
| Who are competitors of Personalis? | Personalis main competitors are Castle Biosciences, Takara Bio, Abclon, Mirxes Holding. |
| What is the current market cap of Personalis? | Personalis' current market cap is $804M. |
| What is the current revenue of Personalis? | Personalis' last 12 months revenue is $72M. |
| What is the current revenue growth of Personalis? | Personalis revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Personalis? | Current revenue multiple of Personalis is 9.7x. |
| Is Personalis profitable? | No, Personalis is not profitable. |
| What is the current EBITDA of Personalis? | Personalis has negative EBITDA and is not profitable. |
| What is Personalis' EBITDA margin? | Personalis' last 12 months EBITDA margin is (116%). |
| What is the current EV/EBITDA multiple of Personalis? | Current EBITDA multiple of Personalis is (8.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.